Old drug, new hope: colchicine may stop Post-Clot leg damage
NCT ID NCT07432529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding colchicine, an anti-inflammatory pill, to standard blood thinners can prevent long-term vein damage after a deep vein thrombosis (DVT) in the leg. About 940 adults with a first acute DVT will receive either colchicine or a placebo for six months and be followed for one year. The goal is to see if colchicine reduces the risk of post-thrombotic syndrome—a condition causing pain, swelling, and skin changes—and prevents new clots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine (an anti-inflammatory drug) taken as a low-dose tablet
What this could lead to
If it works, this could offer a simple, low-cost way to reduce long-term leg pain and swelling after a blood clot.
What could go wrong
This is a large Phase 3 trial, but colchicine may not reduce complications and could cause side effects like stomach upset. Results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••